Genomic Tests

Professional

Treatment

ACTOnco®+ analyzes >400 genes and 13 fusion genes to assist physicians identify the most suitable therapies. Treatment evaluations include targeted therapy, immunotherapy, hormone therapy, and chemotherapy.

Professional

Prediction

ACTRisk™ hereditary gene testing decodes 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes, which provides additional information to a health management strategy.

Professional

Treatment

ACTLiquid™ Pro is a comprehensive NGS-based liquid biopsy assay for pan-solid tumors covering 523 genes and 23 fusion gene variants in circulating tumor DNA. Treatment evaluations include targeted therapy, immunotherapy, and hormone therapy.

Professional

Monitoring

ACTMonitor® Colon analyzes 13 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.

Professional

Monitoring

ACTMonitor® Breast analyzes 8 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.

Professional

Monitoring

ACTMonitor® Lung analyzes 11 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.

Professional

Monitoring

ACTMonitor®+ analyzes 50 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.

Professional

Treatment

ACTCerebra™ sequences 40 druggable genes from Cerebrospinal Fluid (CSF) to identify the most effective targeted therapies based on medical history.

Professional

Treatment

ACTHRD™ detects HRD status by LOH score and 24 HRR-related genes to evaluate whether a tumor is suitable for PARP inhibitors.

Professional

Treatment

ACTBRCA® genetic tests detect mutations in BRCA1/2 genes, which can provide genetic information to evaluate whether a tumor is suitable for PARP inhibitors.

Professional

Treatment

ACTFusion™ is a targeted, multi-biomarker assay that examines 13 druggable fusion genes, and more than 350 known and novel transcripts.

Professional

Treatment

ACTLung™ targets 13 common driver genes and assists newly diagnosed lung cancer patients to rapidly determine a first-line targeted therapy opportunity.

Professional

Treatment

ACTDrug®+ is an NGS-based test, which sequences 40 druggable genes, 13 fusion genes, and more than 350 fusion transcripts simultaneously from cancer specimens.

Patient

Treatment

ACTOnco®+ analyzes >400 genes and 13 fusion genes to assist physicians identify the most suitable therapies. Treatment evaluations include targeted therapy, immunotherapy, hormone therapy, and chemotherapy.

Patient

Prediction

ACTRisk™ hereditary gene testing decodes 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes, which provides additional information to a health management strategy.

Patient

Treatment

ACTLiquid™ Pro is a comprehensive NGS-based liquid biopsy assay for pan-solid tumors covering 523 genes and 23 fusion gene variants in circulating tumor DNA. Treatment evaluations include targeted therapy, immunotherapy, and hormone therapy.

Patient

Monitoring

ACTMonitor® Lung analyzes 11 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.

Patient

Monitoring

ACTMonitor® Colon analyzes 13 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.

Patient

Monitoring

ACTMonitor® Breast analyzes 8 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.

Patient

Monitoring

ACTMonitor®+ analyzes 50 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.

Patient

Treatment

ACTLung™ targets 13 common driver genes and assists newly diagnosed lung cancer patients to rapidly determine a first-line targeted therapy opportunity.

Patient

Treatment

ACTDrug®+ is an NGS-based test, which sequences 40 druggable genes, 13 fusion genes, and more than 350 fusion transcripts simultaneously from cancer specimens.

Patient

Treatment

ACTCerebra™ sequences 40 druggable genes to identify the most effective targeted therapies based on medical history.

Patient

Treatment

ACTHRD™ detects HRD status by LOH score and 24 HRR-related genes to evaluate whether a tumor is suitable for PARP inhibitors.

Patient

Treatment

ACTBRCA® genetic tests detect mutations in BRCA1/2 genes, which can provide genetic information to evaluate whether a tumor is suitable for PARP inhibitors.

Patient

Treatment

ACTFusion™ is a targeted, multi-biomarker assay that examines 13 druggable fusion genes, and more than 350 known and novel transcripts.

Biopharma

Treatment

ACTOnco®+ analyzes >400 genes and 13 fusion genes to assist physicians identify the most suitable therapies. Treatment evaluations include targeted therapy, immunotherapy, hormone therapy, and chemotherapy.

Biopharma

Treatment

ACTLiquid™ Pro is a comprehensive NGS-based liquid biopsy assay for pan-solid tumors covering 523 genes and 23 fusion gene variants in circulating tumor DNA. Treatment evaluations include targeted therapy, immunotherapy, and hormone therapy.

Biopharma

Treatment

ACTDrug®+ is an NGS-based test, which sequences 40 druggable genes, 13 fusion genes, and more than 350 fusion transcripts simultaneously from cancer specimens.

Biopharma

Treatment

ACTLung™ targets 13 common driver genes and assists newly diagnosed lung cancer patients to rapidly determine a first-line targeted therapy opportunity.

Biopharma

Treatment

ACTFusion™ is a targeted, multi-biomarker assay that examines 13 druggable fusion genes, and more than 350 known and novel transcripts.

Biopharma

Treatment

ACTBRCA® genetic tests detect mutations in BRCA1/2 genes, which can provide genetic information to evaluate whether a tumor is suitable for PARP inhibitors.

Biopharma

Treatment

ACTHRD™ detects HRD status by LOH score and 24 HRR-related genes to evaluate whether a tumor is suitable for PARP inhibitors.

Biopharma

Prediction

ACTRisk™ hereditary gene testing decodes 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes, which provides additional information to a health management strategy.

Biopharma

Monitoring

ACTMonitor® Colon analyzes 13 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.

Biopharma

Monitoring

ACTMonitor®+ analyzes 50 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.

Biopharma

Monitoring

ACTMonitor® Breast analyzes 8 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.

Biopharma

Treatment

ACTCerebra™ sequences 40 druggable genes from Cerebrospinal Fluid (CSF) to identify the most effective targeted therapies based on medical history.

Biopharma

Monitoring

ACTMonitor® Lung analyzes 11 forms of circulating tumor DNA in the bloodstream to provide real-time monitoring of drug resistance, early detection of cancer recurrence, and evaluation of treatment response.